(Rockefeller University Press) Researchers from the Albert Einstein College of Medicine in New York have discovered that a signaling protein elevated in patients with acute myeloid leukemia (AML) plays a much wider role in the disease than previously thought. The study, which will be published May 17 in the Journal of Experimental Medicine, raises hopes that current efforts to target this signaling protein could be a successful strategy to treat AML and other blood cancers.

Related Links:

Adding chimeric antigen receptors to T cells (CAR-T), causing them to aggressively target cancer cells, has proven to be a fruitful approach to the treatment of cancer. Like most immunotherapies, it can result in potentially severe side-effects related to excessive immune activation, but it is also quite effective. Treatment of forms of leukemia in particular has produced good results in a large fraction of patients who have trialed the therapy. In the research reported here, scientists extend the chimeric antigen receptor approach to natural killer cells rather than T cells, noting that this may prove to be both safer and…

Source: Fight Aging!Category: Research Authors: Tags: Daily News Source Type: blogs

(Wellcome Trust Sanger Institute) Scientists have discovered that it is possible to identify people at high risk of developing acute myeloid leukemia (AML) years before diagnosis. Wellcome Sanger Institute researchers and collaborators found that patients with AML had genetic changes in their blood years before they suddenly developed the disease. The study published in Nature shows that further research could allow earlier detection and monitoring of people at risk of AML in the future.

(University Health Network) An international team of leukemia scientists has discovered how to predict healthy individuals at risk of developing acute myeloid leukemia (AML), an aggressive and often deadly blood cancer.

AbstractThe myelodysplastic syndromes, the chronic myeloproliferative neoplasms, and the acute myeloid leukemia are malignancies of the myeloid hematopoietic stem cells of the bone marrow. The diseases are characterized by a dysregulation of the immune system as both the cytokine milieu, immune phenotype, immune regulation, and expression of genes related to immune cell functions are deregulated. Several treatment strategies try to circumvent this deregulation, and several clinical and preclinical trials have shown promising results, albeit not in the same scale as chimeric antigen receptor T cells have had in the treatmen…

Publication date: August 2018Source: Hematology/Oncology Clinics of North America, Volume 32, Issue 4Author(s): Sharon A. Savage, Michael F. Walsh


The incidence of acute myeloid leukemia (AML) increases with age, but the outcomes for older adults with AML are poor due to underlying tumor biology, poor tolerance to aggressive treatment, and the physiologic changes of aging. Because of the underlying heterogeneity in health status, treatment decisions are difficult in this population. A geriatric assessment (GA) refers to the use of various validated tools to assess domains that are important in older adults including physical function, cognition, comorbidities, polypharmacy, social support, and nutritional status. In older patients with cancer, a GA can guide …

Source: CancersCategory: Cancer & Oncology Authors: Tags: Review Source Type: research

Publication date: September 2018Source: Biochimica et Biophysica Acta (BBA) – General Subjects, Volume 1862, Issue 9Author(s): Kamalika Sen, Dhananjay Bhattacharyya, Arijita Sarkar, Jyotirmoy Das, Nilanjana Maji, Moitri Basu, Zhumur Ghosh, Tapash Chandra GhoshAbstractBackgroundHuman Chronic and Acute Myeloid Leukemia are myeloproliferative disorders in myeloid lineage of blood cells characterized by accumulation of aberrant white blood cells. In cancer, the anomalous transcriptome includes deregulated expression of non-coding RNAs in conjunction with protein-coding mRNAs in human genome. The coding or non-coding RNA transc…

Publication date: September 2018Source: Human Pathology: Case Reports, Volume 13Author(s): Emily Feldpausch, Shilpa Sambidi, Durga Cherukuri, Jagmohan SidhuAbstractThe myeloproliferative neoplasms (MPNs) are chronic myeloid cancers (clonal hematopoietic disorders) that are characterized by the overproduction of terminally differentiated (mature) blood cells, and that may evolve into acute myeloid leukemia (AML). The literature indicates that three known driver mutations currently exist in BCR/ABL1-negative MPNs: JAK2, MPL and CALR. A small percentage of BCR/ABL1-negative MPN cases lack mutations in all three of these genes…

ConclusionsOur findings indicated that lower expression of BM miR-122 acted as an independent risk factor for OS in CN-AML.

Publication date: 2018Source: Leukemia Research Reports, Volume 9Author(s): Gina Ma, Yi Wang, Tahmeena Ahmed, Ann-Leslie Zaslav, Laura Hogan, Cecilia Avila, Masayuki Wada, Huda SalmanAbstractAberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little in…

Source link


Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image